Research on China Monoclonal Antibody (McAB)

Industry 2014
Email: sales@researchbeam.com Toll Free: +1 (855) 711-1555
Reports Overview
Research on China Monoclonal Antibody (McAB) Industry, 2014 mainly carries on in-depth
analysis on policy environment, global market, Chinese market, as well as the latest
developments of domestic key enterprises related to Chinas monoclonal antibody
industry. Several Chinese large-scale pharmaceutical enterprises devoted themselves to
research and development of monoclonal antibody agents, which have achieved results in
2013. Hengrui Medicine Co., Ltd., Shanghai Pharmaceuticals Co., Ltd. and Qilu Pharm have
applied for clinical research of monoclonal antibody agents. And Walvax Biotechnology
Co., Ltd even made a huge investment in purchasing Genor Biopharma Co., Ltd,
attempting to establish a large biological strategy. Although large-scale pharmaceutical
enterprises entered monoclonal antibody field on a large scale, the overall innovation is
still insufficient, and the market is represented by monoclonal antibody agents and
biological analogue that have submitted applications, few imitated drugs, and innovative
medicines are rare and precious things, mainly on account of high risks and long-time
cycle. Due to late state, Chinas strength on research and development will be still
vulnerable within future three to five years, so it has to open the market preliminarily by
depending on generic drugs.
Reports Overview

In 2013, the market size was CNY 3.8 billion around, up 30% year-on-year; product
categories and sales volume were far less than that of European and American countries.
According to statistical data of Shanghai Pharmaceutical Profession Association (SPPA),
China will see four to six monoclonal antibody agents by 2016, such as Trastuzumab and
Rituximab. And it is expected by 2020, six to ten monoclonal antibody agents will be listed
in market, and some of which are independently researched drugs. Huidian Research
believes that Chinas monoclonal antibody market will embrace its first climax from 2017
to 2020.


Read Complete Report with TOC:
http://www.researchbeam.com/research-on-china-monoclonal-antibody-mcab-
industry-2014-2018-market


Table of Contents
1. Overview of Monoclonal Antibody
1.1 Definition and Characteristics
1.2 Preparation Process of Monoclonal Antibody
1.3 Classification
1.4 Mechanism of Action
1.5 Key Technology

2. Operation Environment of Chinas Monoclonal Antibody Industry
2.1 Analysis of Economic Environment
2.2 Policy Analysis
2.2.1 Monoclonal Antibody Industry Ranks as a Strategic Emerging Industry
2.2.2 NCCN Guidance Supports Monoclonal Antibody Agents; McAB Agents are Included
into Local Health Insurance

3. Current Situation and Tendencies of Worldwide Monoclonal Antibody Industry
3.1 Development History Overview of International Monoclonal Antibody Market

Table of Contents
3.2 Monoclonal Antibody Agents Listing in Market
3.3 Global Key Enterprises Devoting to Developing Monoclonal Antibody Agents
3.4 Powerful Growth Momentum of Global Antibody Market
3.5 Development Tendency and Outlook of Global Monoclonal Antibody Agents
3.5.1 Develop Monoclonal Antibody Aiming at New Target Spots
3.5.2 Diversified Research and Development on Monoclonal Antibody
3.5.3 Antibody-Drug-Conjugates (ADCs) as a New Research Hotspot and Development
Direction
3.5.4 First Monoclonal Antibody Biological Analogue Approved in European and American
Market

4. Operation Situation of Chinas Monoclonal Antibody Industry
4.1 Small Market Size
4.2 Listing Situation of Monoclonal Antibody Agents
4.3 Comparison of Research Progress between China and Foreign Countries
4.3.1 Chinas Research Progress on Monoclonal Antibody

Table of Contents
4.3.2 Differences of New R& D Ability and Industrialization between China and Foreign
Countries
4.4 The First Climax of Monoclonal Antibody: 2017 to 2020

5. Chinas Key Monoclonal Antibody Agent Enterprises
5.1 Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ)
5.1.1 Company Profile
5.1.2 Business Condition
5.1.3 The Generic Drug of Trastuzumab Sai Pu Ting Approved for Clinical Use
5.2 Biotech Pharmaceuticals Co., Ltd.
5.2.1 Company Profile
5.2.2 Business Condition
5.2.3 Production Process
5.3 Chengdu Huasun Biotechnology Co., Ltd.
5.3.1 Company Profile
5.3.2 Representative Products
5.3.3 Business Condition

Table of Contents
5.4 Zhejiang HISUN Pharmaceutical Co., Ltd.
5.4.1 Company Profile
5.4.2 Business Condition
5.4.3 Progress of R & D
5.5 Shanghai Bio Pharmaceutical Co., Ltd.

6. Huge Growth Potential and Development Opportunities of China Monoclonal Antibody
Market in the Future
6.1 Enormous Chinas Market Space and Potential Medical Demand not Get Satisfied
6.2 Late-Mover Advantage and Unique Opportunity of China Monoclonal Antibody Market


To Get Purchase enquriy of Report :
http://www.researchbeam.com/research-on-china-monoclonal-antibody-mcab-industry-
2014-2018-market/purchase-enquiry


Contact us
Cathy Viber
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
Direct: +1 (617) 674-4143
Toll Free: +1 (855) 711-1555
Fax: +1 (855) 550-5975
Web: www.researchbeam.com
Email: sales@researchbeam.com